Rosalind Advisors Inc. Trims Stake in Trevi Therapeutics, Inc. $TRVI

Rosalind Advisors Inc. lowered its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 66.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 100,000 shares of the company’s stock after selling 200,000 shares during the quarter. Trevi Therapeutics comprises approximately 0.3% of Rosalind Advisors Inc.’s portfolio, making the stock its 26th largest holding. Rosalind Advisors Inc. owned approximately 0.08% of Trevi Therapeutics worth $915,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. AQR Capital Management LLC boosted its stake in Trevi Therapeutics by 20.4% during the first quarter. AQR Capital Management LLC now owns 27,720 shares of the company’s stock valued at $174,000 after buying an additional 4,688 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Trevi Therapeutics by 31.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,143 shares of the company’s stock worth $278,000 after acquiring an additional 10,445 shares during the last quarter. Millennium Management LLC increased its stake in Trevi Therapeutics by 356.3% in the 1st quarter. Millennium Management LLC now owns 823,249 shares of the company’s stock worth $5,178,000 after acquiring an additional 642,830 shares during the last quarter. Strs Ohio purchased a new stake in shares of Trevi Therapeutics in the 1st quarter valued at about $52,000. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Trevi Therapeutics in the 2nd quarter valued at about $90,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Wall Street Analysts Forecast Growth

TRVI has been the subject of a number of research analyst reports. Leerink Partners lifted their price target on Trevi Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research report on Monday. Morgan Stanley raised their target price on shares of Trevi Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. Oppenheimer reiterated an “outperform” rating on shares of Trevi Therapeutics in a research report on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $21.10.

Trevi Therapeutics Trading Down 6.2%

TRVI opened at $11.20 on Friday. The stock has a 50-day moving average price of $11.19 and a 200-day moving average price of $10.80. Trevi Therapeutics, Inc. has a 12-month low of $4.85 and a 12-month high of $14.39. The stock has a market capitalization of $1.44 billion, a P/E ratio of -30.27 and a beta of 0.94.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.